Rise in Cancer Treatment Delays in the U.S.

Recent research indicates that the time between a cancer diagnosis and treatment initiation in the U.S. has extended by nearly two weeks over the past decade. This study, published in JAMA Surgery, was conducted by teams from the University of California, Los Angeles and Massachusetts General Hospital. The analysis included data from over two million patients diagnosed with early to locally advanced stages of common cancers such as breast, colon, lung, pancreatic, stomach, and esophageal cancer.

Key Findings

The researchers tracked wait times from the day of diagnosis to the beginning of treatment. This treatment could include surgery or pre-surgical therapy aimed at reducing tumor size. Over the study period, which used data from the National Cancer Database between 2012 and 2023, the median wait times for all six types of cancer increased by more than ten days.

Stomach cancer saw the most significant rise in wait times, from 35 to 49 days. Lung cancer wait times increased from 41 to 53 days. Breast cancer patients waited from 34 to 45 days. Colon cancer delays went from 20 to 31 days. Pancreatic cancer patients waited from 23 to 32 days, and esophageal cancer delays increased from 38 to 48 days. A notable number of patients faced waits of 60 days or longer before starting treatment.

Expert Opinions

Dr. Marc Siegel, a senior medical analyst, commented that this part of the healthcare system needs immediate attention. He pointed out that these delays are noticeable even in high-volume academic medical centers.

While analyzing various factors like age and underlying health, the researchers observed that wait times were disproportionately more extended for specific groups. Black patients, Medicaid users, and individuals in lower-income areas experienced longer delays. Those traveling farther for care or receiving treatment in high-volume hospitals or academic centers waited longer as well.

Regional and Technological Factors

The Western U.S. had longer treatment delays than other regions. Additionally, the use of robotic surgery correlated with extended wait times for non-breast cancers.

Implications and Challenges

The study highlights that delays in surgical treatment can lead to higher mortality and poorer long-term survival, according to previous research. Commentary from Stanford’s Lia D. Delaney, M.D., and Sherry M. Wren, M.D., emphasized that although cancer care has become more sophisticated, regionalization efforts might unintentionally create barriers unless capacity and coordination are improved.

Authors mentioned the study’s limitations, such as its reliance on retrospective data, which could not identify specific reasons for treatment delays like scheduling conflicts, logistical challenges, or patient preferences. The data also did not include when patients first noticed symptoms or sought medical advice.